How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation

• Autor(a) principal: Perini, Guilherme Fleury
• Data de Publicação: 2020
• Outros Autores: Fischer, Thais, Gaiolla, Rafael Dezen [UNESP], Rocha, Talita Bueno, Bellesso, Marcelo, Teixeira, Larissa Lane Cardoso, Delamain, Marcia Torresan, Scheliga, Adriana Alves de Souza, Ribeiro, Glaciano Nogueira, Neto, Jorge Vaz, Baiocchi, Otávio Cesar Carvalho Guimaraes, Abdo, André Neder Ramires, Arrais-Rodrigues, Celso, Fogliatto, Laura M., Bigni, Ricardo de Sá, Schaffel, Rony, Biasoli, Irene, Pereira, Juliana, Nabhan, Samir Kanaan, Souza, Cármino Antônio de, Chiattone, Carlos Sérgio
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNESP
• Texto Completo: http://dx.doi.org/10.1016/j.htct.2020.04.002; http://hdl.handle.net/11449/228792
• topic: Chronic lymphocytic leukemia; Coronavirus; CoVid; CoVId-19; Lymphoid malignancies; Lymphoma

The novel Coronavirus (CoVid-19) outbreak is now consider a world pandemic, affecting more than 1,300,000 people worldwide. Cancer patients are in risk for severe disease, including a higher risk of intensive care unit (ICU) admission, need for invasive ventilation or death. Management of patients with lymphoid malignancies can be challenging during the outbreak, due to need of multiple hospital visits and admissions, immunosuppression and need for chemotherapy, radiotherapy and stem cell transplantation. In this article, we will focus on the practical management of patients with lymphoid malignancies during the COVID-19 pandemic, focusing on minimizing the risk for patients.